News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bristol Myers Squibb Co. (BMY) shares rose by 1.23% on Thursday, closing at $61.51, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. The stock, however, still underperformed compared to some competitors and ended 2.19% below its …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb (BMY) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2026, with Wall Street anticipating $1.59 EPS on $11.67 billion in revenue. The company has a Zacks Earnings ESP of +0.51% and a …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%The U.S. Department of Labor has filed an amicus brief supporting Bristol-Myers Squibb in a pension risk transfer (PRT) appeal, joining business groups, insurers, and states. They argue that retirees lack Article III standing as they still receive full benefits and that allowing such …
Bristol-Myers Squibb (BMY) has gained momentum following FDA acceptance of its New Drug Application for mezigdomide and an AI collaboration with Nvidia for drug discovery. The company is currently considered 3.2% undervalued with a fair value of $62.96, despite existing risks related to patent …
Sharemaestro market context Trend signal active 52 weeks +19.5%This article summarizes Bristow Group's 2026 Annual General Meeting (AGM), held virtually on June 3, 2026. Key outcomes included the confirmation of a quorum, the absence of shareholder proposals, and the nomination of nine individuals for election to the board until the 2027 annual …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (NYSE:BMY) is rolling out new AI infrastructure built on NVIDIA's latest architecture to support drug discovery. The company is applying …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb (BMS) is significantly expanding its AI capabilities by deploying an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, aiming to create the most powerful and energy-efficient NVIDIA infrastructure in life sciences. This investment builds on nearly three years of collaboration …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Washington University in St. Louis and Bristol Myers Squibb have initiated a multiyear collaboration to foster scientific exchange and advance drug development in neuroscience. This partnership will provide WashU medical and research trainees with opportunities to work alongside Bristol Myers Squibb scientists and will …
A recent lobbying disclosure reveals that Bristol-Myers Squibb Company (BMY) reported $3,160,000 in lobbying expenditures for Q2 2026, addressing issues such as drug pricing, intellectual property reform, and the Inflation Reduction Act. The article also details recent congressional stock trading, insider transactions, hedge fund …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb plans to construct "the most powerful AI factory in life sciences" with Nvidia's assistance, marking its expanded collaboration to enhance AI capabilities for complex pharmaceutical problems. Meanwhile, Samsung Biologics is moving to acquire PolyPeptide Group for approximately $1.8 billion, a strategic …
This article first appeared on GuruFocus. Bristol Myers Squibb (NYSE:BMY), a drugmaker focused on creating new medicines, is expanding its three-year partnership with Nvidia, a chipmaker providing artificial intelligence computing technology, to increase the power of its AI factory. Bristol Myers said the system …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb is expanding its computing infrastructure by deploying a second NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems, which provides ten times greater performance per megawatt and will significantly accelerate drug discovery. This investment extends an existing three-year partnership with …
Bristol Myers Squibb is significantly expanding its AI computing infrastructure through a partnership with Nvidia, aiming to create the most powerful AI factory in life sciences. This initiative will leverage Nvidia DGX SuperPOD systems to accelerate research across multiple therapeutic areas, with AI agents …
Bristol Myers Squibb (BMS) is significantly expanding its collaboration with Nvidia by deploying DGX SuperPOD with Vera Rubin NVL72 systems, creating what it claims is the most powerful AI computing infrastructure in life sciences. This aims to accelerate drug discovery and development across various …
Bristol Myers Squibb (BMY) has expanded its artificial intelligence capabilities by implementing Nvidia's (NVDA) DGX SuperPOD with DGX Vera Rubin NVL72 systems. This move is expected to enhance the drugmaker's operations, leveraging Nvidia's supercomputing infrastructure.
Bristol Myers Squibb is expanding its use of artificial intelligence for drug discovery by deploying a second NVIDIA DGX SuperPOD, an "AI factory" built on NVIDIA DGX Vera Rubin NVL72 systems. This initiative aims to provide all scientists with access to a unified AI …
Bristol Myers Squibb Co. is expanding its partnership with Nvidia Corp. to enhance the computing power of its AI factory, aiming to accelerate the development of new medicines. This collaboration is part of a broader trend where the chipmaker partners with the pharma industry …
Bristol-Myers Squibb (BMS) has partnered with Nvidia to establish a dedicated AI supercomputer for drug discovery, leveraging Nvidia's DGX SuperPOD technology. This "AI Center of Excellence" has been operational since March 2024, focusing on oncology research and predicting patient outcomes in immuno-oncology, and has …
Bristol Myers Squibb announced its acquisition of Nvidia's cutting-edge DGX SuperPOD computing system, based on its new Vera Rubin architecture, to enhance AI-driven drug discovery and development. The pharmaceutical company aims to accelerate the identification of drug targets and improve success rates in clinical …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb (BMS) is significantly expanding its AI capabilities by deploying a second NVIDIA DGX SuperPOD, specifically built on eight DGX Vera Rubin NVL72 systems, to create the life science industry's most advanced AI factory. This initiative aims to democratize AI access for …
This article provides key metrics for the VTOL5129959 bond, issued by Bristow Group, Inc. The bond has a 6.875% coupon rate and matures on March 1, 2028. Bristow Group, Inc. is an aviation services company providing support to offshore energy companies and government entities.
This article provides financial information for Bristow Group, Inc. (NYSE: VTOL), specifically its enterprise value to EBIT forward. It is presented in the context of TradingView's platform, offering market data and financial tools for investors. The content primarily highlights a specific financial metric for …
Bristol Myers Squibb and Bain Capital are establishing a new biopharmaceutical company focused on developing therapies for autoimmune diseases. The venture will be launched with $300 million in financing, primarily led by Bain Capital and including funds from the Canada Pension Plan Investment Board. …
Bristol Myers Squibb's stock (BMY) rose 5.5% after the FDA accepted its New Drug Application for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, supported by positive Phase 3 data. This development is crucial for BMS as it aims to strengthen its …
Bristol-Myers Squibb (BMY) reported strong Q2 2024 results with revenues up 9% to $12.2B, driven by its Growth Portfolio, despite Revlimid declines. The company achieved several regulatory approvals and completed major acquisitions, expanding its pipeline. BMY also launched a $1.5B cost-saving initiative and raised …
Bristol-Myers Squibb (BMY) aims for sustained top-tier growth by focusing on transformational medicines, operational excellence, and disciplined capital allocation, having achieved double-digit revenue growth in 2024. The company highlights five key growth products and anticipates next-wave assets like the CELMoD platform and Milvexian to …
Bristol-Myers Squibb (BMY) has seen a 31.9% return in the past year, leading to a mixed valuation picture. While the stock screens as undervalued on some market-based checks, with a fair P/E ratio of 19.2x compared to its current 17.0x, concerns about patent expirations …
Sharemaestro market context Trend signal active 52 weeks +19.5%Bristol-Myers Squibb Co (BMY) stock rose 3.12% on July 15, driven by positive late-stage clinical trial results, increased institutional inflows into the defensive pharmaceutical sector, and favorable technical indicators. Despite facing patent expirations and pricing negotiation risks, the company's diversification strategy and pipeline successes …
Sharemaestro market context Trend signal active 52 weeks +58.2% · Next-week setup positive 55.1%Bristol Myers Squibb (BMY) has seen a 1.8% return over the past month, slightly outperforming the S&P 500 composite. The company's earnings estimates have been revised upwards, with a Zacks Rank #3 (Hold), and it reported strong revenue and EPS beats in the last …
Bristol Myers Squibb (BMY), a biopharmaceutical company within the Zacks Medical - Biomedical and Genetics industry, has a strong track record of surpassing earnings estimates in its last two reports, with an average surprise of 9.64%. With recent estimates moving higher and a positive …
Acorn Growth Companies' Acorn Cap Management has announced the successful completion of the sale of Berry Aviation to Bristow Group Inc. Berry Aviation, a leading provider of specialized aviation services for the U.S. government, will now operate as a standalone business segment within Bristow. …
Acorn Capital Management has sold Berry Aviation, a provider of specialized aviation services, to Bristow Group Inc. The financial terms of the deal were not disclosed, but Bristow's acquisition comes despite a recent mixed financial performance, with Q1 2026 EPS significantly lower than anticipated, …
Search by ticker symbol or company name and select a result to open its chart. The US only control limits results to active US-listed stocks and ETFs.
Showing active US-listed stocks and ETFs only.